KIT mutation

News alerts, weekly reports and conference planners

Entrez ID:

3815

Related biomarkers:

‹

›

KIT mutation	Thymic Carcinoma	KIT mutation	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT mutation	Cutaneous Melanoma	KIT mutation	Cutaneous Melanoma	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2	imatinib Sensitive: A2 - Guideline imatinib Sensitive : A2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B	ripretinib Sensitive: B - Late Trials ripretinib Sensitive : B
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2	imatinib Sensitive: C2 – Inclusion Criteria imatinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
KIT mutation	Melanoma	KIT mutation	Melanoma	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2	regorafenib Sensitive: C2 – Inclusion Criteria regorafenib Sensitive : C2
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	sunitinib + PLX9486 Sensitive: C3 – Early Trials sunitinib + PLX9486 Sensitive : C3	sunitinib + PLX9486 Sensitive: C3 – Early Trials sunitinib + PLX9486 Sensitive : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3
KIT mutation	Cutaneous Melanoma	KIT mutation	Cutaneous Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
KIT mutation	Melanoma	KIT mutation	Melanoma	ripretinib Sensitive: C3 – Early Trials ripretinib Sensitive : C3	ripretinib Sensitive: C3 – Early Trials ripretinib Sensitive : C3
KIT mutation	Melanoma	KIT mutation	Melanoma	temozolomide + rivoceranib Sensitive: C3 – Early Trials temozolomide + rivoceranib Sensitive : C3	temozolomide + rivoceranib Sensitive: C3 – Early Trials temozolomide + rivoceranib Sensitive : C3
KIT mutation	Melanoma	KIT mutation	Melanoma	imatinib + toripalimab-tpzi Sensitive: C3 – Early Trials imatinib + toripalimab-tpzi Sensitive : C3	imatinib + toripalimab-tpzi Sensitive: C3 – Early Trials imatinib + toripalimab-tpzi Sensitive : C3
KIT mutation	Non Small Cell Lung Cancer	KIT mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
KIT mutation	Non Small Cell Lung Cancer	KIT mutation	Non Small Cell Lung Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
KIT mutation	Prostate Cancer	KIT mutation	Prostate Cancer	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3	enzalutamide Resistant: C3 – Early Trials enzalutamide Resistant : C3
KIT mutation	Prostate Cancer	KIT mutation	Prostate Cancer	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials enzalutamide + abiraterone acetate Resistant : C3	enzalutamide + abiraterone acetate Resistant: C3 – Early Trials enzalutamide + abiraterone acetate Resistant : C3
KIT mutation	Prostate Cancer	KIT mutation	Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3	abiraterone acetate Resistant: C3 – Early Trials abiraterone acetate Resistant : C3
KIT mutation	Melanoma	KIT mutation	Melanoma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D	cabozantinib tablet Sensitive: D – Preclinical cabozantinib tablet Sensitive : D

KIT mutation

Associations